Free Trial

Zoetis (ZTS) Competitors

Zoetis logo
$83.97 +0.15 (+0.18%)
As of 03:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ZTS vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy Zoetis stock or one of its competitors? Zoetis's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Zoetis has a net margin of 26.15% compared to Bristol Myers Squibb's net margin of 18.47%. Zoetis' return on equity of 85.90% beat Bristol Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb18.47% 60.48% 14.45%
Zoetis 26.15%85.90%18.39%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bristol Myers Squibb has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Bristol Myers Squibb currently has a consensus target price of $65.46, suggesting a potential upside of 3.27%. Zoetis has a consensus target price of $101.25, suggesting a potential upside of 21.04%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
16 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.47
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.5%. Bristol Myers Squibb pays out 55.9% of its earnings in the form of a dividend. Zoetis pays out 36.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has higher revenue and earnings than Zoetis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.19B2.69$7.05B$4.5114.06
Zoetis$9.49B3.58$2.67B$5.8814.23

In the previous week, Bristol Myers Squibb had 28 more articles in the media than Zoetis. MarketBeat recorded 39 mentions for Bristol Myers Squibb and 11 mentions for Zoetis. Bristol Myers Squibb's average media sentiment score of 0.75 beat Zoetis' score of 0.61 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
15 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Zoetis beats Bristol Myers Squibb on 11 of the 20 factors compared between the two stocks.

How does Zoetis compare to Sanofi?

Sanofi (NASDAQ:SNY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Zoetis had 7 more articles in the media than Sanofi. MarketBeat recorded 11 mentions for Zoetis and 4 mentions for Sanofi. Sanofi's average media sentiment score of 1.00 beat Zoetis' score of 0.61 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.6%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.5%. Sanofi pays out 87.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 36.1% of its earnings in the form of a dividend. Zoetis has increased its dividend for 14 consecutive years.

Zoetis has a net margin of 26.15% compared to Sanofi's net margin of 8.70%. Zoetis' return on equity of 85.90% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Zoetis 26.15%85.90%18.39%

Sanofi has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.38$8.84B$2.0223.95
Zoetis$9.49B3.58$2.67B$5.8814.23

Sanofi has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Sanofi currently has a consensus target price of $53.00, suggesting a potential upside of 9.57%. Zoetis has a consensus target price of $101.25, suggesting a potential upside of 21.04%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Zoetis beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Zoetis compare to GSK?

GSK (NYSE:GSK) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

GSK presently has a consensus price target of $56.30, indicating a potential upside of 11.50%. Zoetis has a consensus price target of $101.25, indicating a potential upside of 21.04%. Given Zoetis' stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
13 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33

GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.5%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.5%. GSK pays out 61.8% of its earnings in the form of a dividend. Zoetis pays out 36.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years.

15.7% of GSK shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GSK has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$43.07B2.37$7.54B$2.8817.53
Zoetis$9.49B3.58$2.67B$5.8814.23

GSK has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Zoetis had 8 more articles in the media than GSK. MarketBeat recorded 11 mentions for Zoetis and 3 mentions for GSK. Zoetis' average media sentiment score of 0.61 beat GSK's score of 0.53 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zoetis has a net margin of 26.15% compared to GSK's net margin of 13.00%. Zoetis' return on equity of 85.90% beat GSK's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK13.00% 41.41% 11.09%
Zoetis 26.15%85.90%18.39%

Summary

Zoetis beats GSK on 15 of the 19 factors compared between the two stocks.

How does Zoetis compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.2%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.5%. Takeda Pharmaceutical pays out 63.2% of its earnings in the form of a dividend. Zoetis pays out 36.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has lower revenue, but higher earnings than Takeda Pharmaceutical. Zoetis is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$4.69T0.01-$1.01B$0.7628.20
Zoetis$9.49B3.58$2.67B$5.8814.23

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zoetis has a consensus target price of $101.25, suggesting a potential upside of 21.04%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Zoetis had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 11 mentions for Zoetis and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.84 beat Zoetis' score of 0.61 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Takeda Pharmaceutical has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Zoetis has a net margin of 26.15% compared to Takeda Pharmaceutical's net margin of 8.26%. Zoetis' return on equity of 85.90% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical8.26% 11.51% 5.59%
Zoetis 26.15%85.90%18.39%

Summary

Zoetis beats Takeda Pharmaceutical on 15 of the 20 factors compared between the two stocks.

How does Zoetis compare to Teva Pharmaceutical Industries?

Zoetis (NYSE:ZTS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Zoetis has a net margin of 26.15% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Zoetis' return on equity of 85.90% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis26.15% 85.90% 18.39%
Teva Pharmaceutical Industries 2.94%33.20%6.59%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zoetis has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Zoetis is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$9.49B3.58$2.67B$5.8814.23
Teva Pharmaceutical Industries$17.26B3.01$1.41B$0.43103.53

Zoetis currently has a consensus target price of $101.25, suggesting a potential upside of 21.04%. Teva Pharmaceutical Industries has a consensus target price of $48.15, suggesting a potential upside of 8.17%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Teva Pharmaceutical Industries had 25 more articles in the media than Zoetis. MarketBeat recorded 36 mentions for Teva Pharmaceutical Industries and 11 mentions for Zoetis. Zoetis' average media sentiment score of 0.61 beat Teva Pharmaceutical Industries' score of 0.56 indicating that Zoetis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
13 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zoetis has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Summary

Zoetis beats Teva Pharmaceutical Industries on 9 of the 16 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZTS vs. The Competition

MetricZoetisPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$34.10B$13.77B$7.84B$23.19B
Dividend Yield2.56%2.58%2.47%3.78%
P/E Ratio14.2729.1234.3429.47
Price / Sales3.597.798.083.17
Price / Cash11.0815.7421.0215.64
Price / Book11.115.204.784.05
Net Income$2.67B$2.88B$3.52B$1.08B
7 Day Performance2.19%-3.46%-4.96%-2.94%
1 Month Performance5.88%-3.62%-3.18%-1.06%
1 Year Performance-30.48%-7.13%-0.28%5.79%

Zoetis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
4.6646 of 5 stars
$83.97
+0.2%
$101.25
+20.6%
-30.7%$34.10B$9.49B14.2714,500
BMY
Bristol Myers Squibb
4.7095 of 5 stars
$62.16
+0.0%
$65.46
+5.3%
+35.8%$131.21B$48.19B10.3032,500
SNY
Sanofi
4.2078 of 5 stars
$48.12
+2.3%
$53.00
+10.1%
-7.2%$115.09B$49.35B9.0674,846
GSK
GSK
3.7555 of 5 stars
$51.47
+2.3%
$56.30
+9.4%
+7.1%$103.46B$43.07B10.7766,841
TAK
Takeda Pharmaceutical
2.375 of 5 stars
$21.09
+0.3%
N/A+49.9%$67.49B$28.32B12.0347,000

Related Companies and Tools


This page (NYSE:ZTS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners